Story · Health Tech · Products

Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition

1 outlet · first reported by MedCity News on

Argenx’s Unnatural Products acquisition brings a macrocyclic peptides discovery platform for developing oral peptide drugs. The deal brings a new modality to Argenx, whose immunology R&D had focused on antibodies. (MedCity News)

Coverage, in order

  1. MedCity News indie
    Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition

    Argenx’s Unnatural Products acquisition brings a macrocyclic peptides discovery platform for developing oral peptide drugs. The deal brings a new modality to Argenx, whose immunology R&D had focused on antibodies.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.